Cargando…

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study

OBJECTIVE: To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS: We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solis-Herrera, Carolina, Triplitt, Curtis, Garduno-Garcia, Jose de Jesús, Adams, John, DeFronzo, Ralph A., Cersosimo, Eugenio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747902/ https://www.ncbi.nlm.nih.gov/pubmed/23579178 http://dx.doi.org/10.2337/dc12-2072

Ejemplares similares

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
por: Cincotta, Anthony H., et al.
Publicado: (2022)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
por: Cersosimo, Eugenio, et al.
Publicado: (2014)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
por: Kubota, Yoshiaki, et al.
Publicado: (2012)

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor
por: Maita, Hiroki, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
por: Komatsu, Tomohiro, et al.
Publicado: (2023)

Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2013)

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
por: Wilson, Jessica R, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control
por: Clarke, Geoffrey D., et al.
Publicado: (2018)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
por: Li, Jingjing, et al.
Publicado: (2014)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
por: Zheng, Wenbin, et al.
Publicado: (2018)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure
por: Qin, Yuejuan, et al.
Publicado: (2023)

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial
por: Yokoh, Hidetaka, et al.
Publicado: (2015)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation
por: Cersosimo, Eugenio, et al.
Publicado: (2014)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats
por: Rofaeil, Remon Roshdy, et al.
Publicado: (2022)

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
por: Clarke, Geoffrey D., et al.
Publicado: (2017)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmcpvb3j822gi07dpfd5j1el9a